If You Invested in Alpha Tau Medical Ltd (DRTS)

Alpha Tau Medical Ltd. (NASDAQ: DRTS) is an Israeli clinical-stage oncology therapeutics company focused on developing Alpha DaRT, a localized alpha-radiation therapy for solid tumors. Founded in 2016, the company concentrates on research, development, and potential commercialization of this technology, which is designed to deliver highly potent radiation directly inside tumors while aiming to spare surrounding healthy tissue.

Alpha Tau’s work centers on Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). The treatment uses intratumoral delivery of radium-224 impregnated sources. As radium-224 decays, short-lived daughter isotopes are released and disperse within the tumor, emitting high-energy alpha particles with the goal of destroying cancer cells. Because these alpha-emitting atoms diffuse only a short distance, Alpha DaRT is intended to mainly affect the tumor itself rather than nearby normal tissue.

Core technology and therapeutic focus

The company’s approach is based on harnessing the relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. According to Alpha Tau, Alpha DaRT is being evaluated in multiple clinical settings, including cancers of the skin, head and neck, pancreas, lung, prostate, and brain. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University, and Alpha Tau is working to translate this concept into clinical practice through a series of trials in different tumor types.

Alpha Tau describes itself as a clinical-stage company, which means its primary activities are related to clinical research, regulatory interactions, and preparation for potential commercialization rather than large-scale marketed product sales. The company has reported that it focuses on patients with solid tumors, including indications with high unmet medical need such as pancreatic cancer and recurrent glioblastoma multiforme (GBM), as well as recurrent cutaneous squamous cell carcinoma (cSCC) and recurrent prostate cancer.

Clinical development programs

Alpha Tau’s news disclosures describe a broad clinical program built around Alpha DaRT:

• Pancreatic cancer (PDAC): The company reported final results from a first-in-human pancreatic cancer study in Montreal for patients with Stage II, III or IV pancreatic ductal adenocarcinoma. The study explored feasibility, safety, and efficacy of endoscopic ultrasound-guided Alpha DaRT. Alpha Tau is also conducting a U.S. multi-center pilot study known as IMPACT (Intratumoral Pancreatic Alpha Combination Trial), evaluating Alpha DaRT in combination with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma.
• Recurrent cutaneous squamous cell carcinoma (cSCC): Alpha Tau has submitted a pre-market approval (PMA) application module to the U.S. Food and Drug Administration (FDA) for Alpha DaRT in recurrent cSCC in patients who are not indicated for surgery or standard radiation therapy and who lack curative systemic options. The company notes that this indication has received Breakthrough Device Designation from the FDA and is being studied in a pivotal U.S. multi-center trial called ReSTART (Recurrent SCC Treatment with Alpha DaRT Radiation Therapy).
• Recurrent glioblastoma multiforme (GBM): Alpha Tau announced treatment of the first patient in a U.S. pilot study for recurrent GBM using Alpha DaRT, marking the first reported use of Alpha DaRT in the brain. The study’s primary objective is to evaluate feasibility and safety in patients with recurrent GBM who are not candidates for surgical resection and have previously received central nervous system radiation.
• Recurrent prostate cancer: The company received FDA approval for an Investigational Device Exemption (IDE) to initiate a pilot study in locally recurrent prostate cancer. The trial is intended to evaluate the safety of Alpha DaRT in patients who have experienced biochemical recurrence after prior external beam radiation therapy, with secondary objectives related to disease progression and survival measures.
• Head and neck and other solid tumors: Alpha Tau has indicated that Alpha DaRT is being evaluated in head and neck tumors and other solid tumors, and has sought marketing authorization in certain regions for recurrent head and neck cancer. The technology is also being studied in additional clinical trials in Europe and the United States.

Regulatory and FDA interactions

Alpha Tau’s disclosures highlight extensive interaction with the U.S. FDA. For recurrent cSCC, recurrent GBM, and recurrent squamous cell carcinoma of the oral cavity, Alpha DaRT has received Breakthrough Device Designation. The company also reports participation in the FDA’s Total Product Life Cycle Advisory Program (TAP), which is described as a program designed to accelerate market access for selected medical technologies. In addition, the FDA has allowed Alpha Tau to use a modular PMA submission framework for Alpha DaRT in recurrent cSCC, enabling the company to submit different components of the application in stages.

Beyond the United States, Alpha Tau has referenced regulatory processes in other jurisdictions, including a request for marketing authorization in Japan for recurrent head and neck cancer. The company also notes that it is working with regulators in multiple regions as it advances Alpha DaRT through clinical and pre-market pathways.

Manufacturing and operational readiness

Alpha Tau has described steps toward preparing for potential commercial-scale production of Alpha DaRT. The company entered into a long-term lease for a manufacturing facility in Hudson, New Hampshire, and reported completion of the first phase of construction. It subsequently obtained a radioactive material license from the State of New Hampshire Bureau of Public Health Protection, Radiological Health Section, for this facility.

According to Alpha Tau, the first phase of the facility is expected to have a nameplate capacity of approximately 400,000 Alpha DaRT sources for local use, subject to operational and clinical assumptions. With the license in place, the company has indicated plans to equip the facility, perform verification and validation activities, and introduce thorium generators with the aim of producing Alpha DaRT treatments at this site.

Financial reporting and public company status

Alpha Tau is listed on the Nasdaq under the symbol DRTS and files reports with the U.S. Securities and Exchange Commission, including Form 20-F annual reports and Form 6-K current reports as a foreign private issuer. The company has reported research and development, marketing, and general and administrative expenses consistent with its clinical-stage status, as well as net losses associated with ongoing development and corporate activities.

In its interim financial statements for the nine months ended September 30, 2025, Alpha Tau presented details on operating expenses, financial income and expenses, and net loss, along with balance sheet data such as cash and cash equivalents, deposits, property and equipment, lease liabilities, and shareholders’ equity. These filings illustrate the company’s focus on funding clinical advancement and preparation for potential commercialization of Alpha DaRT.

Scientific and clinical characteristics of Alpha DaRT

Across its disclosures, Alpha Tau emphasizes several scientific attributes of Alpha DaRT. The therapy is designed to provide highly potent, conformal alpha-irradiation of solid tumors through intratumoral placement of radioactive sources. The short range of alpha particles is intended to confine most of the radiation dose to the tumor volume, with limited penetration into surrounding tissues.

In pancreatic cancer research presented in Montreal and at the ASCO Gastrointestinal Cancers Symposium, Alpha Tau reported disease control rates and objective response rates in patients with advanced pancreatic ductal adenocarcinoma treated with Alpha DaRT, including patients who had received prior chemotherapy. The company also reported observations related to immune and inflammatory markers, describing an immune-preserving profile not typically associated with conventional radiation therapy and a marked reduction in IL-6 cytokine levels in a subset of patients.

In the GBM pilot study, Alpha Tau and its clinical collaborators described a novel delivery approach for intracranial use, including placement of Alpha DaRT sources in a radial configuration to achieve high coverage of the tumor volume while integrating with standard neurosurgical navigation platforms. These details underscore the company’s focus on adapting Alpha DaRT for anatomically complex and sensitive sites.

Engagement with the medical and investment communities

Alpha Tau regularly participates in healthcare and investor conferences, presenting corporate overviews and clinical updates. The company has announced participation in events such as the J.P. Morgan Healthcare Conference, the Jefferies Global Healthcare Conference, and other investor meetings. These activities are described as opportunities to review recent achievements and discuss upcoming data milestones and regulatory interactions.

Through press releases and SEC filings, Alpha Tau provides updates on clinical trial progress, regulatory submissions, manufacturing milestones, and financial results. For investors and observers, DRTS stock represents exposure to a clinical-stage oncology company focused on alpha-radiation therapy for solid tumors, with a central emphasis on the development and potential commercialization of Alpha DaRT.